PensionDanmark Pensionsforsikringsaktieselskab Acquires 54,260 Shares of Merck & Co., Inc. $MRK

PensionDanmark Pensionsforsikringsaktieselskab lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 13.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 462,927 shares of the company’s stock after buying an additional 54,260 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Merck & Co., Inc. were worth $59,486,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $25,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. High Note Wealth LLC grew its stake in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in Merck & Co., Inc. during the fourth quarter worth $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on MRK shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Bank of America boosted their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Barclays upped their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. CICC Research initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $134.56.

Merck & Co., Inc. Trading Down 0.0%

Shares of NYSE:MRK opened at $128.27 on Friday. The business’s 50 day simple moving average is $123.78 and its 200 day simple moving average is $119.04. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company has a market capitalization of $316.81 billion, a P/E ratio of 102.62, a P/E/G ratio of 5.14 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 2.72 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 272.00%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst price-target increase: Guggenheim raised its Merck price target from $145 to $146 and maintained a Buy rating, implying meaningful upside from the referenced share price. This reinforces positive Wall Street sentiment. Benzinga
• Positive Sentiment: Keytruda gains another approval: Health Canada approved Keytruda with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s use and potentially supporting sales before its major patent expirations. Health Canada approves Keytruda treatment
• Positive Sentiment: Pipeline and post-Keytruda strategy: Merck’s second-quarter commentary highlighted new product launches, pipeline progress and efforts to diversify into areas including vaccines, infectious diseases, hematology, cardiopulmonary disease and obesity. The company also raised its 2026 sales outlook, improving confidence in near-term execution. MRK Q2 earnings call
• Neutral Sentiment: Dividend comparison: Merck’s latest results have renewed debate over whether it offers a better income opportunity than Pfizer. The discussion may attract dividend-focused investors, but it does not represent a new company-specific catalyst. Pfizer or Merck dividend comparison
• Negative Sentiment: Keytruda patent risk remains central: Keytruda is approaching a significant patent cliff beginning in 2028. Merck is accelerating acquisitions and partnerships to offset the eventual revenue decline, but those investments can pressure earnings and increase execution risk. Merck is racing beyond Keytruda
• Negative Sentiment: Mixed pipeline development: Merck discontinued tulisokibart development in systemic sclerosis-associated interstitial lung disease, although the drug continues to be evaluated in other indications. The setback highlights clinical-development risk as Merck builds its post-Keytruda portfolio. MSD anti-TL1A trial update

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.